Lilly and Boehringer roll back billions in German investments over health budget cuts

By /

With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.

Scroll to Top